FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2587699915> ?p ?o ?g. }

• W2587699915 endingPage "vi138" @default.
• W2587699915 startingPage "vi138" @default.
• W2587699915 abstract "Current treatment for glioblastoma (GBM) include tumor treating fields (TTFields) in combination with adjuvant temozolomide (TMZ). TTFields are FDA-approval for recurrent and newly diagnosed GBM. TTFields are delivered though a portable, noninvasive device (Optune®, Novocure, Inc, USA) that provides localized treatment. The Optune device captures compliance data through reports that show usage over 28 days of treatment delivered throughout the day. Single-use transducer arrays connected to an electric field generator are applied to the scalp to deliver TTFields. Patient compliance is critical to optimize the overall (OS) survival advantage demonstrated by treated patients. In EF-11, which compared TTFields and provider’s choice chemotherapy in recurrent GBM, patients who received daily treatment for >18 hours daily showed higher OS than <18 hours/daily. Cognitive and emotional functioning measured by the EORTC QLQ-C30 improved from baseline in the TTFields arm. In EF-14, comparing TTFields plus TMZ versus TMZ alone in newly-diagnosed GBM, cognitive functioning, emotional functioning, physical functioning, role functioning, and social functioning did not significantly decline with TTFields plus TMZ. It is imperative that patients and their family be educated on complying with 18 hour/daily treatment duration. Discussions on short, daily treatment breaks, daily exercise regimen if feasible, and other resources (‘loosely woven’ cranial prosthesis, wigs, sun-protecting hats) can help educate and facilitate compliance with 18 hour/daily treatment duration. The noninvasive aspect of TTFields precludes typical systemic side effects associated with chemotherapy. Adverse events associated with TTFields are mild to moderate (grade 1-2) skin irritation, which are easily managed, reversible, and didn’t result in treatment discontinuation. The correlation of patient compliance with improved survival and reduced toxicities underscores importance of providing comprehensive patient/family education on use of TTFields in GBM by the treatment team. Data analyses on patient and family education provided by an interdisciplinary treatment team is ongoing and will be presented." @default.
• W2587699915 created "2017-02-17" @default.
• W2587699915 creator A5010643457 @default.
• W2587699915 creator A5011888074 @default.
• W2587699915 creator A5018934758 @default.
• W2587699915 creator A5059417712 @default.
• W2587699915 creator A5063863193 @default.
• W2587699915 creator A5072791860 @default.
• W2587699915 creator A5085801807 @default.
• W2587699915 date "2016-11-01" @default.
• W2587699915 modified "2023-09-26" @default.
• W2587699915 title "NIMG-63. OPTIMAL PATIENT AND FAMILY EDUCATION IS KEY TO IMPROVING THE EFFICACY OF TUMOR TREATING FIELDS PLUS CHEMOTHERAPY IN TREATMENT OF GBM" @default.
• W2587699915 doi "https://doi.org/10.1093/neuonc/now212.574" @default.
• W2587699915 hasPublicationYear "2016" @default.
• W2587699915 type Work @default.
• W2587699915 sameAs 2587699915 @default.
• W2587699915 citedByCount "0" @default.
• W2587699915 crossrefType "journal-article" @default.
• W2587699915 hasAuthorship W2587699915A5010643457 @default.
• W2587699915 hasAuthorship W2587699915A5011888074 @default.
• W2587699915 hasAuthorship W2587699915A5018934758 @default.
• W2587699915 hasAuthorship W2587699915A5059417712 @default.
• W2587699915 hasAuthorship W2587699915A5063863193 @default.
• W2587699915 hasAuthorship W2587699915A5072791860 @default.
• W2587699915 hasAuthorship W2587699915A5085801807 @default.
• W2587699915 hasBestOaLocation W25876999151 @default.
• W2587699915 hasConcept C126322002 @default.
• W2587699915 hasConcept C143998085 @default.
• W2587699915 hasConcept C197934379 @default.
• W2587699915 hasConcept C2776694085 @default.
• W2587699915 hasConcept C2777389519 @default.
• W2587699915 hasConcept C2781413609 @default.
• W2587699915 hasConcept C71924100 @default.
• W2587699915 hasConceptScore W2587699915C126322002 @default.
• W2587699915 hasConceptScore W2587699915C143998085 @default.
• W2587699915 hasConceptScore W2587699915C197934379 @default.
• W2587699915 hasConceptScore W2587699915C2776694085 @default.
• W2587699915 hasConceptScore W2587699915C2777389519 @default.
• W2587699915 hasConceptScore W2587699915C2781413609 @default.
• W2587699915 hasConceptScore W2587699915C71924100 @default.
• W2587699915 hasIssue "suppl_6" @default.
• W2587699915 hasLocation W25876999151 @default.
• W2587699915 hasOpenAccess W2587699915 @default.
• W2587699915 hasPrimaryLocation W25876999151 @default.
• W2587699915 hasRelatedWork W1974029597 @default.
• W2587699915 hasRelatedWork W1984282923 @default.
• W2587699915 hasRelatedWork W2072172607 @default.
• W2587699915 hasRelatedWork W2073885660 @default.
• W2587699915 hasRelatedWork W2104071976 @default.
• W2587699915 hasRelatedWork W2357953144 @default.
• W2587699915 hasRelatedWork W2373226427 @default.
• W2587699915 hasRelatedWork W2387456186 @default.
• W2587699915 hasRelatedWork W2388730008 @default.
• W2587699915 hasRelatedWork W757206253 @default.
• W2587699915 hasVolume "18" @default.
• W2587699915 isParatext "false" @default.
• W2587699915 isRetracted "false" @default.
• W2587699915 magId "2587699915" @default.
• W2587699915 workType "article" @default.